Spectrum Pharmaceuticals Suspends Phase 3 Poziotinib Trial in HER2 NSCLC

The registry entry for the poziotinib study in HER2 exon 20-mutated lung cancer now reads SUSPENDED, with no patients enrolled and a redesign under discussion with the FDA.